Editas Medicine, Inc. Common Stock
EDIT Real Time Price USDRecent trades of EDIT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EDIT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 May 06, 2020 Issue: Health Issues Medicare/Medicaid
-
$40,000 Apr 26, 2020 Issue: Health Issues
-
$50,000 Apr 20, 2020 Issue: Medicare/Medicaid Health Issues
-
$40,000 Feb 03, 2020 Issue: Health Issues
-
$50,000 Jan 21, 2020 Issue: Health Issues Medicare/Medicaid
-
$40,000 Nov 01, 2019 Issue: Health Issues
-
$50,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 Aug 06, 2019 Issue: Health Issues
-
$50,000 Jul 22, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 May 03, 2019 Issue: Health Issues
-
$50,000 Apr 19, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 Jan 23, 2019 Issue: Health Issues
-
$45,000 Jan 18, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 Oct 25, 2018 Issue: Health Issues
-
$45,000 Oct 18, 2018 Issue: Medicare/Medicaid Health Issues
-
$40,000 Aug 01, 2018 Issue: Health Issues
-
$45,000 Jul 20, 2018 Issue: Health Issues Medicare/Medicaid
-
$40,000 Apr 20, 2018 Issue: Health Issues
-
$45,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues
-
$45,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code
-
$40,000 Jan 22, 2018 Issue: Health Issues
-
$40,000 Oct 20, 2017 Issue: Health Issues
-
$45,000 Oct 19, 2017 Issue: Health Issues Defense
-
$15,000 Jul 20, 2017 Issue: Health Issues
-
$40,000 Jul 19, 2017 Issue: Health Issues
-
$40,000 Apr 19, 2017 Issue: Health Issues
-
$50,000 Jan 23, 2017 Issue: Health Issues
-
$60,000 Oct 19, 2016 Issue: Health Issues
-
$40,000 Jul 21, 2016 Issue: Health Issues
Estimated quarterly lobbying spending
EDIT Revenue by Segment or Geography
New patents grants
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Apr. 01, 2025
-
Patent Title: Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) Feb. 25, 2025
-
Patent Title: Compositions and methods for promoting homology directed repair Jan. 21, 2025
-
Patent Title: Methods of assessing nuclease cleavage Oct. 08, 2024
-
Patent Title: Cas9 fusion molecules, gene editing systems, and methods of use thereof Jul. 30, 2024
-
Patent Title: Systems and methods for the treatment of hemoglobinopathies Jul. 09, 2024
-
Patent Title: Crispr/rna-guided nuclease systems and methods Apr. 23, 2024
-
Patent Title: Crispr/cas-related methods and compositions for improving transplantation Feb. 27, 2024
-
Patent Title: Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites Jan. 09, 2024
-
Patent Title: Systems and methods for the treatment of hemoglobinopathies Dec. 26, 2023
-
Patent Title: Crispr/cas-related methods and compositions for treating herpes simplex virus Dec. 05, 2023
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Jul. 04, 2023
-
Patent Title: Methods for improving crispr/cas-mediated genome-editing Jun. 20, 2023
-
Patent Title: Use of exonucleases to improve crispr/cas-mediated genome editing Jun. 06, 2023
-
Patent Title: Genome editing systems comprising repair-modulating enzyme molecules and methods of their use Mar. 07, 2023
-
Patent Title: Compositions and methods for treating cep290 associated disease Jan. 31, 2023
-
Patent Title: Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency Nov. 29, 2022
-
Patent Title: Methods and systems for analyzing guide rna molecules Nov. 15, 2022
-
Patent Title: Crispr-related methods and compositions with governing grnas Jul. 19, 2022
-
Patent Title: Optimized crispr/cas9 systems and methods for gene editing in stem cells Jul. 19, 2022
-
Patent Title: Crispr/cas-related methods and compositions for treating herpes simplex virus Jul. 19, 2022
-
Patent Title: Compositions and methods for treating cep290-associated disease May. 24, 2022
-
Patent Title: Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) Mar. 08, 2022
-
Patent Title: Crispr/cas-related methods and compositions for treating sickle cell disease Feb. 08, 2022
-
Patent Title: Cas9 fusion molecules, gene editing systems, and methods of use thereof Feb. 01, 2022
-
Patent Title: Evaluation of cas9 molecule/guide rna molecule complexes Nov. 23, 2021
-
Patent Title: Compositions and methods for treating cep290-associated disease Oct. 12, 2021
-
Patent Title: Engineered cas9 nucleases Aug. 24, 2021
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Jun. 08, 2021
-
Patent Title: Crispr/cas-related methods and compositions for treating cystic fibrosis Jun. 08, 2021
-
Patent Title: Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa Jun. 08, 2021
-
Patent Title: Crispr/cas-related methods and compositions for treating herpes simplex virus May. 11, 2021
-
Patent Title: Crispr-related methods and compositions with governing grnas May. 05, 2020
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Dec. 03, 2019
-
Patent Title: Engineered cas9 nucleases Oct. 01, 2019
-
Patent Title: Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) Apr. 09, 2019
-
Patent Title: Crispr-related methods and compositions with governing grnas Jan. 29, 2019
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Jun. 26, 2018
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna May. 08, 2018
-
Patent Title: Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) Apr. 10, 2018
-
Patent Title: Crispr-related methods and compositions with governing grnas Dec. 05, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to EDIT
Recent picks made for EDIT stock on CNBC
ETFs with the largest estimated holdings in EDIT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $EDIT stock a Buy, Sell, or Hold?
- What is the price target for $EDIT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $EDIT stock?
- Who owns the most shares of $EDIT stock?
- What funds own $EDIT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view EDIT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.